| Literature DB >> 35321000 |
Xinlei Hao1, Shuoran Zhao1, Jiajia Cheng1, Lihua Yang1, Haiming Jiang1, Fuzheng Qu2.
Abstract
Objective: To evaluate the clinical efficacy of nasal high-flow oxygen therapy in patients with acute left heart failure and hypoxemia.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35321000 PMCID: PMC8938071 DOI: 10.1155/2022/7117508
Source DB: PubMed Journal: J Healthc Eng ISSN: 2040-2295 Impact factor: 2.682
Comparison of clinical data between the two groups of patients.
| Patient characteristics | Control group ( | Experimental group ( |
|
|---|---|---|---|
| Age (years, | 101.19 ± 15.59 | 87.7 ± 15.5 |
|
| Male (composition ratio, %) | 24.58 ± 3.80 | 18.88 ± 2.77 |
|
| Complications (composition ratio, %) | 103.48 ± 16.95 | 88.90 ± 13.95 |
|
| Ejection fraction (%) | 85.8 ± 7.35 | 95.72 ± 2.2 |
|
Summary of the comparison of the effective rates of the two treatment methods.
| Project | High-flow oxygen therapy group | Ordinary oxygen therapy group |
|---|---|---|
| Effective number of cases | 67 | 55 |
| Efficient | 95.7% | 78.6% |
Summary of changes in indicators in the high-flow oxygen therapy group before and after treatment.
| Project | High-flow oxygen therapy group |
|
| |
|---|---|---|---|---|
| Before therapy | After treatment | |||
| HR | 101.19 ± 15.59 | 87.7 ± 15.5 | 18.8 |
|
| RR | 24.58 ± 3.80 | 18.88 ± 2.77 | 19.7 |
|
| MAP | 103.48 ± 16.95 | 88.90 ± 13.95 | 12.1 |
|
| SaO2 | 85.8 ± 7.35 | 95.72 ± 2.2 | −12.4 |
|
| pH value | 7.31 ± 0.63 | 7.38 ± 0.51 | −12.2 |
|
| PaO2 | 58.78 ± 8.48 | 83.24 ± 13.31 | −17.7 |
|
| PaCO2 | 50.51 ± 10.88 | 41.52 ± 7.66 | 9.53 |
|
| Lac | 3.39 ± 2.83 | 2.09 ± 2.09 | 8.69 |
|
| EF value | 46.21 ± 9.07 | 56.36 ± 5.92 | −13.4 |
|
| NT-proBNP | 12057.61 ± 9547.99 | 8136.80 ± 7607.01 | 7.03 |
|
Summary of changes in various indicators before and after treatment in the ordinary oxygen therapy group.
| Project | Normal oxygen therapy group |
|
| |
|---|---|---|---|---|
| Before therapy | After treatment | |||
| HR | 91.05 ± 14.37 | 80.5 ± 14.02 | 18.2 |
|
| RR | 22.36 ± 4.04 | 19.07 ± 3.37 | 10.8 |
|
| MAP | 99.05 ± 12.97 | 88.33 ± 11.66 | 13.1 |
|
| SaO2 | 86.4 ± 4.81 | 93.44 ± 2.98 | −15.5 |
|
| pH value | 7.33 ± 0.09 | 7.37 ± 0.59 | −4.5 |
|
| PaO2 | 58.65 ± 4.87 | 79.29 ± 9.07 | −20.0 |
|
| PaCO2 | 50.35 ± 6.90 | 42.80 ± 5.35 | 15.8 |
|
| Lac | 3.34 ± 2.32 | 2.52 ± 1.77 | 7.1 |
|
| EF value | 47.53 ± 12.78 | 51.31 ± 10.45 | −7.7 |
|
| NT-proBNP | 8074.15 ± 5464.43 | 6328.04 ± 4550.46 | 10.0 |
|
The improvement of various indicators before and after treatment in the high-flow oxygen therapy group and the ordinary oxygen therapy group.
| Project (difference before and after treatment) | High-flow oxygen therapy group | Normal oxygen therapy group |
|
|
|---|---|---|---|---|
| HR | 15.5 ± 6.7 | 10.6 ± 4.3 | 46.9 |
|
| RR | 5.7 ± 2.4 | 3.3 ± 2.3 | 18.2 |
|
| MAP | 14.6 ± 9.9 | 10.7 ± 6.1 | 10.8 |
|
| SaO2 | 9.9 ± 6.5 | 7 ± 3.4 | 13.1 |
|
| pH value | 0.071 ± 0.048 | 0.058 ± 0.038 | 25.4 |
|
| PaO2 | 24.5 ± 11.3 | 20.6 ± 7.7 | 11.4 |
|
| PaCO2 | 9.0 ± 7.7 | 7.6 ± 3.5 | 20 |
|
| Lac | 1.3 ± 1.2 | 0.8 ± 0.9 | 15.9 |
|
| EF value | 10.1 ± 6.2 | 3.8 ± 3.6 | 7.1 |
|
| NT-proBNP | 3920.1 ± 4566.1 | 1746.1 ± 1290.3 | 7.7 |
|